Compound 814
Identifiers
- Canonical SMILES:
C[C@H]1C[C@H](CCN1Cc1ccccc1-c1ccc(Cl)cc1)N1CCc2c(C1)ncnc2NS(=O)(=O)c1ccc(N[C@H](CCN(C)C)CSc2ccccc2)c(c1)S(=O)(=O)C(F)(F)F
- IUPAC name:
N-[7-[(2S)-1-[[2-(4-chlorophenyl)phenyl]methyl]-2-methylpiperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide
- InChi:
InChI=1S/C45H51ClF3N7O4S3/c1-31-25-36(20-23-55(31)27-33-9-7-8-12-39(33)32-13-15-34(46)16-14-32)56-24-21-40-42(28-56)50-30-51-44(40)53-63(59,60)38-17-18-41(43(26-38)62(57,58)45(47,48)49)52-35(19-22-54(2)3)29-61-37-10-5-4-6-11-37/h4-18,26,30-31,35-36,52H,19-25,27-29H2,1-3H3,(H,50,51,53)/t31-,35+,36-/m0/s1
- InChiKey:
ZWWWHJCPYOPUEX-NUHNATIRSA-N
External links
168317997 |
External search
Bibliography (1)
Publication | Name |
---|---|
Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff, Novartis Ag. . Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer None. | 4 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 7.66 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 941.28 g/mol | |||
HBA | 11 | |||
HBD | 2 | |||
HBA + HBD | 13 | |||
AlogP | 7.07 | |||
TPSA | 127.84 | |||
RB | 16 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
WO2011029842 | 4 | BCL2 P10415 |
|
Biochemical assay | Surface Plasmon Resonance | pIC50 (half maximal inhibitory concentration, -log10) | 7.66 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5000 | Navitoclax | DB12340 | |
0.3910 | N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE | DB06899 | |
0.3910 | Sulfaisodimidine | DB13283 | |
0.3906 | GDC-0349 | DB13072 | |
0.3784 | Presatovir | DB12165 | |
0.3754 | N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE | DB07800 | |
0.3658 | Quinupristin | DB01369 | |
0.3602 | Sparsentan | DB12548 | |
0.3564 | Tianeptine | DB09289 | |
0.3546 | 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine | DB07585 | |
0.3538 | Sulfametomidine | DB13485 | |
0.3502 | 4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE | DB04673 | |
0.3494 | N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]Quinolizin-12(2h)-Yl]Propyl}Propane-2-Sulfonamide | DB01967 | |
0.3487 | PF-232798 | DB14813 | |
0.3466 | Elobixibat | DB12486 |